Added Benefit Of Eribulin In Breast Cancer Is Not Proven

[News]

Eribulin (trade name: Halaven®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy...

More... (http://www.medicalnewstoday.com/releases/249128.php)